Aclarion, Inc.ACON

Aclarion, Inc. is a cash-heavy, revenue-light medical-technology outfit whose public voice promises to “revolutionise spine care” while its 10-Q quietly records just $21,140 in sales for the quarter that ended 31 March 2026. The company’s cash pile stands at $19 million-enough to keep the lights on for another year or two, but not enough to fund a full-scale commercial rollout of its AI-driven Nociscan platform. The gap between the marketing slide and the filing line is wider than a lumbar disc bulge.

What Aclarion actually sells is a cloud-based SaaS that analyses patient data for clinics looking to standardise spine-care pathways. The product is rooted in a clutch of US and foreign patents, and the company claims early adopters in the US, EU, and UK, yet none of the official pages ties those adopters to measurable revenue. The “limited commercial launch” described on the “About” page is exactly that: limited, with no disclosed user counts or per-clinic fees. When Aclarion announced a partnership with PRIA Healthcare to advance reimbursement and commercial adoption, the press release did not include a signed contract value, a pilot cohort size, or even a timeline for first claims submissions.

According to the 10-Q filed on 24 May 2026, Aclarion reported revenues of $21,140, a net loss attributable to parent of $2.9 million, an operating loss of $3.0 million, and a net cash burn from operations of $2.6 million for the quarter ending 31 March 2026. Total assets stood at $20.6 million, of which $19 million was held in cash and cash equivalents, while liabilities were a modest $986,208 and stockholders’ equity was $19.7 million. Research and development expense for the quarter was $315,417, capitalised software development costs were immaterial, and the company spent only $21,528 on property, plant, and equipment in the full year to 31 December 2025. Diluted loss per share was $1.34 on 2.1 million diluted shares. The 8-K ownership tables filed on 12 June 2026 show insider stakes but do not disclose any director loans or share pledges to cover operating losses.

The company’s product news page lists two clinical abstracts and the addition of a Texas spine centre as a new CLARITY site, but none of the items quotes revenue, contract value, or even a named fee schedule. The “patents” page confirms a portfolio of IP filings without stating which claims are granted or which are still under examination. Aclarion’s official site and news page therefore function as marketing brochures rather than audited disclosures of commercial traction.

Without an evidence trail that ties Nociscan usage to contracted payments, the revenue line will remain a rounding error. The cash runway is visible on the balance sheet, but the commercial runway is invisible in the filings. The next catalyst that would materially change the file is a disclosed customer contract with a minimum revenue commitment or a published cohort of paying sites with utilisation metrics. Until then, the platform story outruns the platform receipts.